Cargando…
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
BACKGROUND: Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood–brain barrier for late-stage infection. These procedures are inconvenient in rural...
Autores principales: | Kande Betu Ku Mesu, Victor, Mutombo Kalonji, Wilfried, Bardonneau, Clélia, Valverde Mordt, Olaf, Ngolo Tete, Digas, Blesson, Séverine, Simon, François, Delhomme, Sophie, Bernhard, Sonja, Mahenzi Mbembo, Hélène, Mpia Moke, Christian, Lumeya Vuvu, Steven, Mudji E'kitiak, Junior, Akwaso Masa, Felix, Mukendi Ilunga, Melchias, Mpoyi Muamba Nzambi, Dieudonné, Mayala Malu, Tim, Kapongo Tshilumbwa, Serge, Botalema Bolengi, Franck, Nkieri Matsho, Mathieu, Lumbala, Crispin, Scherrer, Bruno, Strub-Wourgaft, Nathalie, Tarral, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220131/ https://www.ncbi.nlm.nih.gov/pubmed/34143998 http://dx.doi.org/10.1016/S2214-109X(21)00208-4 |
Ejemplares similares
-
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
por: Kande Betu Kumesu, Victor, et al.
Publicado: (2022) -
Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
por: Valverde Mordt, Olaf, et al.
Publicado: (2022) -
Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection
por: Ngay Lukusa, Ipos, et al.
Publicado: (2021) -
Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study
por: Ngay Lukusa, Ipos, et al.
Publicado: (2022) -
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
por: Betu Kumeso, Victor Kande, et al.
Publicado: (2023)